Articlenpj biomedical innovations2025
Targeted amplification of alternating electric fields using ferroelectric nanoparticles.
Article in npj biomedical innovations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Smart Nanoformulations for Oncology: A Review on Overcoming Biological Barriers with Active Targeting, Stimuli-Responsive, and Controlled Release for Effective Drug Delivery.Pharmaceutics · 2026Review
- Dual-modal Fe-MOF-derived piezoelectric nanofibers enable combinatorial tumor suppression via tumor treating fields and magnetic hyperthermia.Science and technology of advanced materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Electric field (e-field)-based therapies like tumor-treating fields (TTFields) are promising non-invasive cancer treatments, but their clinical utility is limited by shallow tissue penetration, low spatial specificity, and potential thermal side effects. This study presents surface-engineered tetragonal phase barium titanate nanoparticles (tBTO NPs) that locally amplify weak e-fields to improve therapy. Stable dispersion and targeted delivery of tBTO NPs in biological environments, without detectable cytotoxicity, are achieved through precise surface chemical modifications. Comparative experiments underscore the critical role of ferroelectricity: tBTO NPs exhibit superior microtubule disruption and cell growth inhibition than non-ferroelectric Au or low-ferroelectric cubic phase BTO NPs. Super-resolution microscopy and single-cell tracking quantitatively demonstrate how amplified e-fields perturb cellular behaviors, including migration, proliferation, and morphology. Overall, tBTO NPs may address TTField limitations and advance nanomaterial-based bioelectronic cancer therapies, broadening the use of electromagnetic technologies in precision medicine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.